1.7709
Schlusskurs vom Vortag:
$1.68
Offen:
$1.72
24-Stunden-Volumen:
3.78M
Relative Volume:
2.29
Marktkapitalisierung:
$168.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-134.24M
KGV:
-1.0005
EPS:
-1.77
Netto-Cashflow:
$-121.34M
1W Leistung:
+14.75%
1M Leistung:
-26.37%
6M Leistung:
-76.66%
1J Leistung:
-61.12%
Annexon Inc Stock (ANNX) Company Profile
Firmenname
Annexon Inc
Sektor
Branche
Telefon
(650)-822-5500
Adresse
1400 SIERRA POINT PARKWAY, BRISBANE
Vergleichen Sie ANNX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ANNX
Annexon Inc
|
1.765 | 168.95M | 0 | -134.24M | -121.34M | -1.77 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
488.82 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
585.19 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
600.32 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.41 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
253.34 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-12-21 | Hochstufung | BofA Securities | Neutral → Buy |
2023-10-30 | Eingeleitet | Wells Fargo | Overweight |
2023-05-26 | Herabstufung | BofA Securities | Buy → Neutral |
2023-05-25 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-09-16 | Eingeleitet | Jefferies | Buy |
2022-09-09 | Eingeleitet | BTIG Research | Buy |
2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
2021-09-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-01-26 | Eingeleitet | Needham | Buy |
2020-08-18 | Eingeleitet | BofA Securities | Buy |
2020-08-18 | Eingeleitet | Cowen | Outperform |
2020-08-18 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Annexon Inc Aktie (ANNX) Neueste Nachrichten
ANNX’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Alliancebernstein L.P. Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Sees Large Decrease in Short Interest - Defense World
JPMorgan Chase & Co. Has $7.75 Million Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Annexon Strengthens Team with Strategic Equity Package: Inside the $1.54 Share Grant - Stock Titan
Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (NASDAQ:ANNX) - Seeking Alpha
Vanguard Group Inc. Buys 576,625 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
KLP Kapitalforvaltning AS Takes $98,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
American Century Companies Inc. Has $916,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder - AOL.com
Why Annexon Inc. (ANNX) Went Down On Thursday? - Yahoo Finance
Annexon Touts ‘Rapid’ and ‘Durable’ Improvements for Targeted Guillain-Barré Therapy - BioSpace
Annexon Highlights Pivotal Data on First Potential Targeted Ther - GuruFocus
Annexon Cites 'Durable Benefit' of Tanruprubart in Guillain-Barre Syndrome Trial - MarketScreener
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting - The Manila Times
Annexon Highlights Pivotal Data on First Potential Targeted - GlobeNewswire
First-Ever Targeted GBS Therapy Achieves Remarkable Recovery Rates in Landmark Trial - Stock Titan
Prudential Financial Inc. Boosts Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon stock hits 52-week low at $1.73 amid sharp annual decline - Investing.com
Annexon Highlights Leadership in Advancing Clinical - GlobeNewswire
First-Ever Targeted GBS Treatment: Annexon's Phase 3 Data Could Change Patient Care - Stock Titan
Teacher Retirement System of Texas Makes New $106,000 Investment in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Here's Why We're Not Too Worried About Annexon's (NASDAQ:ANNX) Cash Burn Situation - Yahoo Finance
135,000 Shares in Annexon, Inc. (NASDAQ:ANNX) Purchased by Swiss National Bank - Defense World
Annexon Inc (NASDAQ: ANNX) Slashes -7.49%: The Most Likely Path Going Forward - Stocks Register
Annexon, Inc. (NASDAQ:ANNX) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Annexon stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
Annexon stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
Bank of New York Mellon Corp Acquires 6,226 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Inc (NASDAQ: ANNX): Down -60.53% In 2025, Outlook Remains Negative - Stocks Register
Annexon Inc (ANNX) With A Potential Upside Of More Than -460.0% - Stocks Register
Quarterly Metrics: Quick and Current Ratios for Annexon Inc (ANNX) - The Dwinnex
Annexon (ANNX) Projected to Post Earnings on Tuesday - Defense World
Annexon Strengthens Team with 35,000-Share Stock Option Grant to Key New Hire - StockTitan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
19,895 Shares in Annexon, Inc. (NASDAQ:ANNX) Acquired by Arizona State Retirement System - Defense World
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - markets.businessinsider.com
Annexon: Despite Major Catalysts, Stock Is Trading Almost At Cash (NASDAQ:ANNX) - Seeking Alpha
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of “Buy” by Analysts - Defense World
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely - simplywall.st
Rhumbline Advisers Purchases 5,854 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Q1 Earnings Forecast for Annexon Issued By HC Wainwright - Defense World
Annexon Biosciences: Promising Developments and Strategic Milestones Justify Buy Rating - TipRanks
Q2 Earnings Estimate for Annexon Issued By HC Wainwright - Defense World
Analysts Set Expectations for Annexon FY2025 Earnings - Defense World
New York State Common Retirement Fund Purchases 20,311 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Potential Price Increase for Annexon Inc (ANNX) After Recent Insider Activity - Knox Daily
Annexon stock price target cut to $20 at H.C. Wainwright By Investing.com - Investing.com Canada
Annexon (NASDAQ:ANNX) Given “Buy” Rating at Needham & Company LLC - Defense World
Finanzdaten der Annexon Inc-Aktie (ANNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):